Literature DB >> 16495723

Effects of monoamine oxidase inhibitors on cocaine discrimination in rats.

Michael B Gatch1, Cynthia M Taylor, Elva Flores, Meghan Selvig, Michael J Forster.   

Abstract

This study tested the time course of the discriminative stimulus effects of inhibitors of monoamine oxidase alone or in combination with cocaine. Male Sprague-Dawley rats were trained to discriminate cocaine (10 mg/kg, intraperitoneal) from saline using a two-lever choice methodology. The nonselective monoamine oxidase inhibitors tranylcypromine (0.01-5 mg/kg) and phenelzine (1-25 mg/kg), the monoamine oxidase-A selective compound clorgyline (1-25 mg/kg), and the monoamine oxidase-B selective compounds pargyline (0.005-50 mg/kg) and selegiline (1-25 mg/kg) were tested for substitution 15 min or 24 h following administration, and in combination with 10 mg/kg of cocaine 24 and 48 h after administration. At 15 min, selegiline fully substituted for the discriminative stimulus effects of cocaine, whereas all other compounds partially substituted. At 24 h, substitution of cocaine was diminished for all compounds except phenelzine, which produced a greater amount of substitution at 24 h than at 15 min. When cocaine was administered 24 h after clorgyline, selegiline, pargyline, and phenelzine, cocaine-appropriate responding was attenuated at intermediate doses of these drugs, whereas the highest doses did not alter cocaine-lever responding. All compounds except selegiline substantially decreased response rate and produced various adverse effects. At 48 h, the effects of all compounds except phenelzine were markedly reduced. Selectivity for monoamine oxidase-A or monoamine oxidase-B did not predict the ability to substitute for or attenuate the subjective effects of cocaine. These findings suggest that monoamine oxidase inhibitors can modulate the discriminative stimulus effects of cocaine for at least 24 h, and may be useful for treatment of cocaine abuse.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495723      PMCID: PMC3867205          DOI: 10.1097/01.fbp.0000197459.08892.b5

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  31 in total

1.  Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction.

Authors:  Richard B Resnick
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

2.  Failure to detect amphetamine or 1-amino-3-phenylpropane in humans or rats receiving the MAO inhibitor tranylcypromine.

Authors:  R L Sherry; G Rauw; K F McKenna; P R Paetsch; R T Coutts; G B Baker
Journal:  J Affect Disord       Date:  2000-12       Impact factor: 4.839

Review 3.  Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction.

Authors:  Susan E Robinson
Journal:  CNS Drug Rev       Date:  2002

4.  Time-dependent changes in brain monoamine oxidase activity and in brain levels of monoamines and amino acids following acute administration of the antidepressant/antipanic drug phenelzine.

Authors:  M B Parent; M K Habib; G B Baker
Journal:  Biochem Pharmacol       Date:  2000-05-15       Impact factor: 5.858

Review 5.  Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs.

Authors:  N H Neff; H Y Yang
Journal:  Life Sci       Date:  1974-06-01       Impact factor: 5.037

6.  Selective radiochemical labeling of types A and B active sites of rat liver monoamine oxidase.

Authors:  D J Edwards; K Y Pak
Journal:  Biochem Biophys Res Commun       Date:  1979-01-30       Impact factor: 3.575

7.  Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors.

Authors:  J Bergman; S Yasar; G Winger
Journal:  Psychopharmacology (Berl)       Date:  2001-09-06       Impact factor: 4.530

8.  Involvement of Ca2+ in dopamine release in striatal rat slices by PF9601N and L-deprenyl.

Authors:  V Pérez; M Pastó; M Unzeta
Journal:  Neurobiology (Bp)       Date:  2000

9.  Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria.

Authors:  G Bartzokis; M Beckson; T Newton; M Mandelkern; J Mintz; J A Foster; W Ling; T P Bridge
Journal:  Neuropsychopharmacology       Date:  1999-06       Impact factor: 7.853

10.  Transdermal selegiline and intravenous cocaine: safety and interactions.

Authors:  Elisabeth J Houtsmuller; Lisa D Notes; Thomas Newton; Nicolette van Sluis; Nora Chiang; Ahmed Elkashef; George E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  2003-11-06       Impact factor: 4.530

View more
  1 in total

Review 1.  Human drug discrimination: A primer and methodological review.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; Craig R Rush
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.